DEFINIUM THERAPEUTIC (DFTX) insider trading activity (SEC Form 4). Over the trailing 90 days, DFTX insiders filed 0 purchases totalling $0 and 5 sales totalling $2.6M — net SELLING of $2.6M. Most recent filing: Jun 26, 2026. Insider transactions are a Pro-tier alertable signal in the live Top Tier Newswire terminal — Form 4 filings reach the wire within minutes of acceptance by the SEC. Data shown publicly here is delayed 4 hours.
| Filed | Insider | Role | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Wiley Matthew T. | Chief Commercial Officer | S Sale | — | $45.03 | $129K | filing |
| Jun 26, 2026 | Karlin Daniel | Chief Medical Officer | S Sale | — | $45.03 | $452K | filing |
| Jun 26, 2026 | Barrow Robert | CEO | S Sale | — | $45.03 | $1.3M | filing |
| Jun 26, 2026 | Roberts Brandi | CFO | S Sale | — | $45.03 | $136K | filing |
| Jun 26, 2026 | Sullivan Mark | GC | S Sale | — | $45.03 | $586K | filing |